Editor’s Briefing: September 9, 2026

In Short. Autoimmunity and “cold” tumors dominated the tape: an oral TLR7/8 lupus hit headed for phase 3, a second itch-receptor miss forced a migraine pivot, a third Spyre IBD antibody cleared induction, and a $225 million CTLA-4 bet aimed squarely at microsatellite-stable colon cancer.

---

Lupus, oral, into pivotal

Beeline Medicines published phase 2 results for afimetoran, an oral small-molecule inhibitor of Toll-like receptors 7 and 8 that Bristol Myers Squibb had already taken through early safety and cutaneous lupus work before the asset moved. After 48 weeks of daily dosing in systemic lupus erythematosus, all three afimetoran doses beat placebo on the SLE Responder Index-4 primary endpoint, with a reported p-value below 0.001. Secondary endpoints moved in the same direction. Beeline has not yet released dose-level numbers beyond that significance call. (Fierce Biotech)

The company plans pivotal programs in both SLE and cutaneous lupus, entering a field where Merck KGaA’s enpatoran is already in phase 3 on the same TLR7/8 idea, while GSK’s Benlysta, AstraZeneca’s Saphnelo, and a Roche Gazyva review sketch the biologic baseline. Beeline arrived with spring capital and an explicit preference to take winners through approval alone. The teachable claim for readers is mechanistic: genetic and experimental work that put TLR7 gain-of-function on the lupus map is now being tested as a daily pill against an SRI-4 bar Roche also used.

When the itch target fails twice

Evommune’s EVO756, an MRGPRX2 antagonist, missed its primary endpoint in a 121-person phase 2 atopic dermatitis study at week 12, and it missed the secondaries with it. That follows a June miss in urticaria. The company will not pursue atopic dermatitis with the asset. It will keep a phase 2b migraine-prevention study open and shift attention toward EVO301, an IL-18 binding-protein fusion that already posted a phase 2 eczema win earlier this year. Shares fell roughly 18 percent on the news. (Fierce Biotech)

Two fails in itch-adjacent indications do not automatically kill a receptor program, yet they do force a clean rewrite of the thesis. Migraine is a different clinical claim. Readers should treat EVO756 as a molecule under a new question, not as a delayed dermatitis story.

IBD’s three-antibody platform keeps clearing bars

Spyre Therapeutics reported that SPY003, an anti-IL-23 antibody, met primary and secondary endpoints in Part A of the Skyline ulcerative colitis induction study. In 44 patients, the company cited a 10-point reduction from baseline in Robarts Histopathology Index by week 12, clinical remission by modified Mayo Score of 20 percent, and endoscopic improvement of 30 percent. SPY001 (α4β7) and SPY002 (TL1A) had already cleared their own phase 2 induction readouts earlier in 2026. Part B will test two dose levels of the monotherapies and combinations, with combination data pointed at 2027. (Fierce Biotech)

Platforms earn trust when each arm can stand alone on induction metrics before the combination story arrives. Spyre is now asking readers to wait for the harder test: whether stacking three mechanisms improves the efficacy and dosing profile enough to matter against today’s standard of care.

Money for a colder colon cancer

Solstice Oncology closed a $225 million series A, led by RA Capital, to push porustobart, an Fc-enhanced CTLA-4 antibody licensed from Harbour BioMed, into a Keytruda combination phase 2 in microsatellite-stable stage II and III colon cancer. Enrollment is due this year, with a readout aimed at the second half of 2027. Solstice paid a $105 million upfront package for ex-China rights and argues neoadjuvant use, a shorter half-life than first-generation CTLA-4 drugs, and Harbour phase 1b response signals justify the cold-tumor bet. CEO Caroline Loew told Fierce that PD-1 alone sits near a 0 percent response rate in this setting, that first-generation CTLA-4 combinations reach about 5 percent, and that Harbour’s early combo work showed responses around 30 percent with an 8.4-month average remission. (Fierce Biotech)

Those early figures are the claim to watch, not the financing headline. Agenus is preparing its own CTLA-4 plus PD-1 combination for MSS colon cancer. The race is whether second-generation CTLA-4 chemistry plus earlier timing can open a tumor class immunotherapy has mostly skipped.

Cell therapy and angioedema on the sideboard

Bristol Myers Squibb said Quintessential, a pivotal trial of arlocabtagene autoleucel (arlo-cel), a GPRC5D-directed CAR-T, met its primary overall-response endpoint and a key complete-response secondary in patients who had already cycled through immunomodulatory drugs, proteasome inhibitors, anti-CD38 therapy, and BCMA-targeted treatment. Numbers wait for a medical meeting. The strategic point is a post-BCMA target that can compete with J&J’s Talvey bispecific on a one-and-done cell-therapy schedule. (Fierce Biotech)

Pharvaris added a second phase 3 win for oral deucrictibant, this time as once-daily extended-release prophylaxis in CHAPTER-3: an 83 percent reduction in monthly hereditary angioedema attack rates versus placebo at 24 weeks (87 percent in type 1/2), with secondaries also met. An on-demand immediate-release filing already carries an April 23, 2027 PDUFA, and a prophylactic NDA is planned for the first half of 2027. (Fierce Biotech)

Schrödinger spun Tectora Therapeutics with a $55 million series A and two early oral immunology programs from its computational chemistry bench, keeping equity plus milestones while the new company stays in stealth. (Fierce Biotech)

What to watch

pdufa.bio (updated September 9) still shows Telix’s TLX101-Px decision in two days, Ultragenyx UX111 (ABO-102) for Sanfilippo A on September 19, and a late-September cluster that includes Merck Winrevair label work, Incyte/Mirum zilurgisertib, Novo Mim8, and Scholar Rock apitegromab. After Ultragenyx’s Aspire miss earlier this month, the September 19 UX111 date is a commercial-path catalyst, not a redo of Angelman.

For mechanism readers, the open questions are sharper than the financings. Can TLR7/8 oral inhibition clear pivotal SRI-4 bars against enpatoran’s head start. Does MRGPRX2 retain any clinical claim once dermatitis and urticaria are closed. Will Spyre’s three antibodies still look best-in-class once combinations, not monotherapies, carry the weight. And can neoadjuvant CTLA-4 enrichment turn Harbour’s early MSS colon signals into a randomized phase 2 that survives contact with Agenus and with surgery-timed immune reality.